Search

Displaying results 4211 - 4220 of 10000 in total
  1. Drug

    Enoxacin

    go.drugbank.com/drugs/DB00467
    Approved

    A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.

    Categories: Topoisomerase II Inhibitors
  2. Drug

    Nimesulide

    go.drugbank.com/drugs/DB04743
    ApprovedInvestigationalWithdrawn

    Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries. … Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.

    Products: NI-M-DOL® (NIMESULIDA SUSPENSION), MESULID SUSPENSION PARA ADMINISTRACIÓN EN GOTAS
  3. Drug

    Cethromycin

    go.drugbank.com/drugs/DB06419
    Investigational

    Cethromycin is a 3-keto (ketolide) derivative of erythromycin A with an 11,12-carbamate group and an O-6-linked aromatic ring system. … [L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA.

  4. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc. … Faropenem medoxomil is an ester prodrug derivative of the beta-lactam antibiotic [faropenem].

  5. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

  6. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim. … NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy.

  7. Drug

    Brolucizumab

    go.drugbank.com/drugs/DB14864
    ApprovedInvestigational

    [L9089] Brolucizumab was granted FDA approval in October 2019.[L9089] … Brolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.

  8. Drug

    TRC093

    go.drugbank.com/drugs/DB06356
    Investigational

    TRC093 is a recombinant humanized IgG1k monoclonal antibody.

  9. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  10. Drug

    Nitrofurantoin

    go.drugbank.com/drugs/DB00698
    ApprovedInvestigationalVet approved

    [A179824] This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. … [A179824] Nitrofurantoin is a second line treatment to [trimethoprim]/[sulfamethoxazole].[A179830] Nitrofurantoin was granted FDA approval on 6 February 1953.[L6895]

    Synonyms: N-(5-Nitrofurfurylidene)-1-aminohydantoin